Recombinant modified vaccinia virus Ankara influenza vaccine
AssigneeBavarian Nordic A/S
InventorsJosef Weigl, Jürgen Hausmann, Robin Steigerwald
Life of this patent
Estimating the term…
Abstract
The invention concerns a recombinant modified vaccinia virus Ankara (MVA virus) expressing at least two external influenza virus antigens and/or an epitope of one or more of the at least two antigens and at least two internal influenza virus antigens and/or an epitope of the at least two antigens. The invention, thus, concerns a recombinant MVA virus encoding multiple external and/or internal influenza virus antigens, preferably from multiple influenza virus strains. The invention further concerns the use of said recombinant MVA in preparing a medicament and vaccine for influenza virus. Further encompassed by the present invention are methods, composition and kits.
Claims20
A modified vaccinia virus Ankara (MVA) comprising at least 11,000 nucleotides of influenza nucleic acid sequences encoding at least 5 external influenza virus antigens and at least 3 internal influenza virus antigens, wherein the nucleic acid sequences encoding the antigens are inserted into at least two MVA insertion sites,
- wherein the external influenza virus antigens comprise at least 3 different hemagglutinin antigens selected from hemagglutinin 2 (H2), hemagglutinin 9 (H9), hemagglutinin 5 (H5), and hemagglutinin 7 (H7) antigens.
A method for generating a modified vaccinia virus Ankara (MVA) expressing at least 5 external influenza virus antigens and at least 3 internal influenza virus antigens comprising inserting at least 11,000 nucleotides of influenza nucleic acid sequences encoding the antigens into at least two MVA insertion sites and isolating the resultant recombinant virus,
- wherein the external influenza virus antigens comprise at least 3 different hemagglutinin antigens selected from hemagglutinin 2 (H2), hemagglutinin 9 (H9), hemagglutinin 5 (H5), and hemagglutinin 7 (H7) antigens.
A method for generating an immune response comprising administering to an animal a modified vaccinia virus Ankara (MVA) comprising at least 11,000 nucleotides of influenza nucleic acid sequences expressing at least 5 external influenza virus antigens and at least 3 internal influenza virus antigens, wherein the nucleic acid sequences encoding the antigens are inserted into at least two MVA insertion sites,
- wherein the external influenza virus antigens comprise at least 3 different hemagglutinin antigens selected from hemagglutinin 2 (H2), hemagglutinin 9 (H9), hemagglutinin 5 (H5), and hemagglutinin 7 (H7) antigens.
Dependencies are inferred from the claim text.